Related Experiment Video
Updated: May 15, 2026
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Locoregional therapy for cholangiocarcinoma
Jan B Kuhlmann1, Hubert E Blum
1Department of Medicine II, University Hospital Freiburg, Freiburg, Germany. jan.kuhlmann@uniklinik-freiburg.de
Current Opinion in Gastroenterology
|January 23, 2013
Summary
Locoregional therapies offer a promising strategy for intrahepatic cholangiocarcinoma, improving local tumor control and potentially prolonging overall survival when used with or without systemic chemotherapy.
Area of Science:
- Hepatobiliary surgery
- Oncology
- Interventional radiology
Background:
- Cholangiocarcinoma (CCA) presents a poor prognosis, with surgical resection being the only curative option but feasible in only ~30% of patients.
- Recurrence rates after resection approach 60%, leading to low 5-year overall survival (OS).
- Systemic chemotherapy for unresectable CCA yields an OS of less than 1 year.
Purpose of the Study:
- To review locoregional therapy concepts for cholangiocarcinoma (CCA).
- To highlight the potential of locoregional interventions in managing CCA, particularly when curative resection is not possible.
Main Methods:
- Review of recent studies on locoregional therapies for intrahepatic cholangiocarcinoma.
- Analysis of outcomes associated with radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and radiation therapy (external/internal).
Main Results:
- Locoregional therapies, including RFA, TACE, and radiation, have demonstrated promising results in intrahepatic cholangiocarcinoma.
- These methods contribute to local tumor control, a critical factor in improving patient outcomes.
Conclusions:
- Locoregional therapies are effective in managing intrahepatic cholangiocarcinoma.
- Achieving local tumor control through locoregional interventions, alone or combined with systemic chemotherapy, can prolong overall survival.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...